Hypertensive Crises and Phenylpropanolamine

Gibson, Gretchen; Warrell, D A

doi:10.1016/s0140-6736(72)91893-4

Cited by 24 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have focused on relatively low doses of drugs since the administration of high doses has ethical implications because of their association with hazardous side-effects. In particular, phenylpropanolamine use has been linked with hypertensive reactions, cerebral haemorrhage and psychosis [1,11,14,16]. Although this study assessed the effects of low doses of ephedrines, the purpose of the multiple dosing regimen applied was to provide a situation where individuals were administered maximal therapeutic doses.…”

Section: Discussionmentioning

confidence: 99%

Physiological, Subjective and Performance Effects of Pseudoephedrine and Phenylpropanolamine During Endurance Running Exercise

2003

View full text Add to dashboard Cite

The aim of the study was to assess the effect of maximal therapeutic dosing of sympathomimetic amines found in over-the-counter (OTC) decongestant preparations on endurance running. Following familiarisation and a graded exercise test to determine maximal oxygen uptake (VO2 max), trained male runners (n = 8) completed four exercise sessions each separated by a minimum of one week. Each session was comprised of 20 min of sub-maximal treadmill running (70 % VO2 max) followed by a 5,000-m time trial on the treadmill under drug, placebo or control conditions. Drugs were administered in their commercial format over the 36-hour period prior to testing in the manufacturer's recommended maximal doses (i. e. 25 mg of phenylpropanolamine and 60 mg of pseudoephedrine four times daily). During sub-maximal endurance running no statistical differences were observed in heart rate, VO2, minute ventilation, respiratory exchange ratio, blood lactate, glucose or non-esterified fatty acids (NEFA) or ratings of perceived exertion with respect to the treatment administered. Similarly there were no statistical differences according to the condition during the 5,000-m running time trial, in terms of heart rate, ratings of perceived exertion, time of completion and pre and post exercise blood lactate, glucose or NEFA. The results indicate that in maximal, multiple therapeutic doses both pseudoephedrine or phenylpropanolamine as present in common OTC decongestant formulations do not affect, nor possess any ergogenic properties with regard to, endurance running.

show abstract

Section: Discussionmentioning

confidence: 99%

Physiological, Subjective and Performance Effects of Pseudoephedrine and Phenylpropanolamine During Endurance Running Exercise

2003

View full text Add to dashboard Cite

show abstract

Pharmacology and safety of phenylpropanolamine

Johnson¹

1991

Drug Development Research

View full text Add to dashboard Cite

INTRODUCTION ABSTRACT Johnson, D.A.: Pharmacology and safety of phenylpropanolamine. Drug Dev. Res. 22: 197-207. 1991. Phenylpropanolamine (PPA) is a phenylethylamine found commonly in cough medicines, nasal decongestants, and over-the-counter (OTC) diet aids. Since its discovery more than 70 years ago, the pharmacology of this drug has periodically been reexamined as the result of advances in the understanding of the sympathetic nervous system and adrenergic receptor function. This review presents a brief overview of the pharmacology of PPA, with an emphasis on how the drug effects smooth muscle tissues. Additionally, since the safety of PPA has recently been called into question, research pertaining to its toxicity is also reviewed.

show abstract

The Pharmacology of α‐Adrenergic Decongestants

Johnson

Hricik

1993

Pharmacotherapy

View full text Add to dashboard Cite

The mechanism by which decongestants produce their action is activation of postjunctional α‐adrenergic receptors found on precapillary and postcapillary blood vessels of the nasal mucosa. Activation of these receptors by either direct binding of the sympathomimetic agent to the binding site of the receptor, or by the enhanced release of norepinephrine produces vasoconstriction. Such vasoconstriction decreases blood flow through the nasal mucosa and results in shrinkage of this tissue. Decongestants can be administered topically, directly onto the nasal mucosa, or orally. Prolonged topical administration may produce rebound congestion. Oral decongestants can affect the cardiovascular, urinary, central nervous, and endocrine systems. Overdose can produce medically significant increases in blood pressure as well as central nervous system stimulation.

show abstract

Hypertensive Crises and Phenylpropanolamine

Cited by 24 publications

References 12 publications

Physiological, Subjective and Performance Effects of Pseudoephedrine and Phenylpropanolamine During Endurance Running Exercise

Physiological, Subjective and Performance Effects of Pseudoephedrine and Phenylpropanolamine During Endurance Running Exercise

Pharmacology and safety of phenylpropanolamine

The Pharmacology of α‐Adrenergic Decongestants

Contact Info

Product

Resources

About